Meeder Asset Management’s Arcutis Biotherapeutics ARQT Stock Holding History

Meeder Asset Management’s Portfolio ARQT Stock Details ARQT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-1,032	Closed	-$20K	–	865
2022 Q3	$20K	Buy	+1,032	New	+$23.4K	﹤0.01%	1100
2021 Q4	–	Sell	-2,683	Closed	-$64K	–	1215
2021 Q3	$64K	Buy	2,683 +406	+18%	+$9.26K	﹤0.01%	1021
2021 Q2	$62K	Buy	2,277 +904	+66%	+$25.5K	﹤0.01%	1052
2021 Q1	$40K	Buy	+1,373	New	+$42.9K	﹤0.01%	1175
2020 Q4	–	Sell	-403	Closed	-$11K	–	1869
2020 Q3	$11K	Buy	+403	New	+$10.8K	﹤0.01%	1332
2020 Q2	–	Sell	-14	Closed	–	–	2045
2020 Q1	$0	Buy	+14	New	+$376	﹤0.01%	2320

Other funds holding ARQT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Meeder Asset Management's ARQT Position: Q4 2022 in Review

Meeder Asset Management sold out of Arcutis Biotherapeutics (ARQT) in Q4 2022, closing a stake of 1,032 shares — an estimated $20K sold.

Meeder Asset Management first reported a position in ARQT in Q1 2020 and held it in 6 quarters. The position peaked at $64K in Q3 2021. 141 funds tracked by Wall St. Rank hold ARQT as of Q4 2022.

Meeder Asset Management reported no remaining Arcutis Biotherapeutics position as of Q4 2022 after selling out during the quarter.
Meeder Asset Management sold 1,032 Arcutis Biotherapeutics shares in Q4 2022, an estimated $20K.
Meeder Asset Management first reported a position in Arcutis Biotherapeutics in Q1 2020 and held it in 6 quarters.
Meeder Asset Management's Arcutis Biotherapeutics position peaked at $64K in Q3 2021.
141 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q4 2022.

Based on Meeder Asset Management's 13F filing for Q4 2022, filed 14 Feb 2023.